Search

We consider the associated production of a vector or Higgs boson with a jet in hadronic collisions. When the transverse momentum q T of the boson-jet system is much smaller than its invariant mass Q , the QCD perturbative expansion is affected by large logarithmic terms that must be resummed to all orders. We discuss the all-order resummation structure of the logarithmically enhanced contributions up to next-to-leading logarithmic accuracy. Resummation is performed at the differential level with respect to the kinematical variables of the boson-jet system. Soft-parton radiation produces azimuthal correlations that are fully accounted for in our framework. We present explicit analytical results for the resummation coefficients up to next-to-leading order and next-to-leading logarithmic accuracy, that include the exact dependence on the jet radius., (© The Author(s) 2022.)

We consider the simultaneous measurement of the Higgs (p_{t}^{H}) and the leading jet (p_{t}^{J}) transverse momentum in hadronic Higgs-boson production, and perform the resummation of the large logarithmic corrections that originate in the limit p_{t}^{H},p_{t}^{J}≪m_{H} up to next-to-next-to-leading-logarithmic order. This work constitutes the first simultaneous (double differential) resummation for two kinematic observables of which one involves a jet algorithm in hadronic collisions, and provides an important milestone in the theoretical understanding of joint resummations. As an application, we provide precise predictions for the Higgs transverse-momentum distribution with a veto p_{t}^{J}≤p_{t}^{J,v} on the accompanying jets, whose accurate description is relevant to the Higgs precision programme at the Large Hadron Collider.

We present accurate QCD predictions for the transverse momentum ( p ⊥ ) spectrum of electroweak gauge bosons at the LHC for 13 TeV collisions, based on a consistent combination of a NNLO calculation at large p ⊥ and N 3 LL resummation in the small p ⊥ limit. The inclusion of higher order corrections leads to substantial changes in the shape of the differential distributions, and the residual perturbative uncertainties are reduced to the few percent level across the whole transverse momentum spectrum. We examine the ratio of p ⊥ distributions in charged- and neutral-current Drell-Yan production, and study different prescriptions for the estimate of perturbative uncertainties that rely on different degrees of correlation between these processes. We observe an excellent stability of the ratios with respect to the perturbative order, indicating a strong correlation between the corresponding QCD corrections., (© The Author(s) 2019.)

We present a determination of the parton distribution functions of the proton in which NLO and NNLO fixed-order calculations are supplemented by NLL x small- x resummation. Deep-inelastic structure functions are computed consistently at NLO+NLL x or NNLO+NLL x , while for hadronic processes small- x resummation is included only in the PDF evolution, with kinematic cuts introduced to ensure the fitted data lie in a region where the fixed-order calculation of the hard cross-sections is reliable. In all other respects, the fits use the same methodology and are based on the same global dataset as the recent NNPDF3.1 analysis. We demonstrate that the inclusion of small- x resummation leads to a quantitative improvement in the perturbative description of the HERA inclusive and charm-production reduced cross-sections in the small x region. The impact of the resummation in our fits is greater at NNLO than at NLO, because fixed-order calculations have a perturbative instability at small x due to large logarithms that can be cured by resummation. We explore the phenomenological implications of PDF sets with small- x resummation for the longitudinal structure function F L at HERA, for parton luminosities and LHC benchmark cross-sections, for ultra-high-energy neutrino-nucleus cross-sections, and for future high-energy lepton-proton colliders such as the LHeC.

We present a new set of parton distributions, NNPDF3.1, which updates NNPDF3.0, the first global set of PDFs determined using a methodology validated by a closure test. The update is motivated by recent progress in methodology and available data, and involves both. On the methodological side, we now parametrize and determine the charm PDF alongside the light-quark and gluon ones, thereby increasing from seven to eight the number of independent PDFs. On the data side, we now include the D0 electron and muon W asymmetries from the final Tevatron dataset, the complete LHCb measurements of W and Z production in the forward region at 7 and 8 TeV, and new ATLAS and CMS measurements of inclusive jet and electroweak boson production. We also include for the first time top-quark pair differential distributions and the transverse momentum of the Z bosons from ATLAS and CMS. We investigate the impact of parametrizing charm and provide evidence that the accuracy and stability of the PDFs are thereby improved. We study the impact of the new data by producing a variety of determinations based on reduced datasets. We find that both improvements have a significant impact on the PDFs, with some substantial reductions in uncertainties, but with the new PDFs generally in agreement with the previous set at the one-sigma level. The most significant changes are seen in the light-quark flavor separation, and in increased precision in the determination of the gluon. We explore the implications of NNPDF3.1 for LHC phenomenology at Run II, compare with recent LHC measurements at 13 TeV, provide updated predictions for Higgs production cross-sections and discuss the strangeness and charm content of the proton in light of our improved dataset and methodology. The NNPDF3.1 PDFs are delivered for the first time both as Hessian sets, and as optimized Monte Carlo sets with a compressed number of replicas., (© The Author(s) 2017.)

We present an unbiased determination of the charm content of the proton, in which the charm parton distribution function (PDF) is parametrized on the same footing as the light quarks and the gluon in a global PDF analysis. This determination relies on the NLO calculation of deep-inelastic structure functions in the FONLL scheme, generalized to account for massive charm-initiated contributions. When the EMC charm structure function dataset is included, it is well described by the fit, and PDF uncertainties in the fitted charm PDF are significantly reduced. We then find that the fitted charm PDF vanishes within uncertainties at a scale [Formula: see text] GeV for all [Formula: see text], independent of the value of [Formula: see text] used in the coefficient functions. We also find some evidence that the charm PDF at large [Formula: see text] and low scales does not vanish, but rather has an "intrinsic" component, very weakly scale dependent and almost independent of the value of [Formula: see text], carrying less than [Formula: see text] of the total momentum of the proton. The uncertainties in all other PDFs are only slightly increased by the inclusion of fitted charm, while the dependence of these PDFs on [Formula: see text] is reduced. The increased stability with respect to [Formula: see text] persists at high scales and is the main implication of our results for LHC phenomenology. Our results show that if the EMC data are correct, then the usual approach in which charm is perturbatively generated leads to biased results for the charm PDF, though at small x this bias could be reabsorbed if the uncertainty due to the charm mass and missing higher orders were included. We show that LHC data for processes, such as high [Formula: see text] and large rapidity charm pair production and [Formula: see text] production, have the potential to confirm or disprove the implications of the EMC data.

Purpose: We evaluated the antiemetic efficacy of tropisetron, a 5-HT3 receptor antagonist, during its compassionate use in children with malignant disease who during previous chemotherapy cycles experienced emesis refractory to metoclopramide-based treatments., Patients and Methods: Tropisetron was given to 15 children (eight boys and seven girls 18 months to 18 years of age) with miscellaneous neoplasms. Generally 5 mg/day of tropisetron was administered i.v. the first day of cisplatin-based chemotherapy and i.v. or orally each subsequent day of chemotherapy. The dose of tropisetron was reduced to 2 mg/day in children < 2 years of age and weighing < 20 kg., Results: Vomiting was well controlled (no more than two episodes per day) on 118 of the 184 days of treatment with tropisetron (64%). No clinically important variations were observed in blood pressure, heart rate, body temperature, or electrocardiographic findings attributable to tropisetron. Transient, mild to moderate side effects (headache, constipation, abdominal pain, diarrhea) occurred in five patients on 11 of the 184 days of tropisetron treatment (6%)., Conclusion: The results obtained during compassionate use of tropisetron confirm that it is a valid, safe, and manageable antiemetic for the treatment of pediatric patients.

One hundred and twenty-one consecutive patients with monostotic Ewing's sarcoma (ES) were treated according to three consecutive combined modality programs from 1974 to 1986. Their 3-year progression free survival (PFS) rate from diagnosis of 59% was identical to the event free survival (EFS) rate, since all the 50 events occurring within 3 years from diagnosis were tumor recurrences. Primary tumor was treated with radiotherapy in 75 cases, surgical resection plus radiotherapy in 38, and radical surgery in 8. Chemotherapy was given to all patients and each program included adriamycin, vincristine, and cyclophosphamide +/- dactinomycin. Median follow-up was 12 years, ranging from 6 to 19 years. The PFS rate decreased to 49% at 6 years and plateaued at 46% after the 7th year from diagnosis, even though some relapses were observed as late as 14 years from diagnosis. Second malignancies developed in 7 patients free from progressive ES and were represented by osteogenic sarcoma in previously irradiated bone in 4 cases and by breast carcinoma in 3. No other event but tumor relapse or second malignancy occurred in this series. EFS rate was 47% at 6 years and 39% at 12 years, further decreasing in the following years because of a number of late events. A continuous PFS longer than 7 years may be consistent with cure in the majority of patients with monostotic ES. However, these patients should be followed indefinitely because of risk of second malignancies.

Twenty-four consecutive patients with nondysgerminomatous germ cell tumor of the ovary were treated after surgery with cisplatin, vinblastine, and bleomycin (PVB regimen). The cycle was repeated every 3 weeks for three to five courses. Fourteen patients had endodermal sinus tumor, and 10 had mixed germ cell tumors. Stage of disease (FIGO, 1986) was as follows: stage I, 6; stage IIc-IV, 17; and recurrence, 1 patient. All patients were monitored by alpha-fetoprotein and human chorionic gonadotropin. Only 1 patient had received previous chemotherapy. All 5 patients without residual disease and with negative marker levels in which PVB was used as adjuvant treatment were free of disease for a median duration of 59 months from the start of PVB. Of the 19 patients with measurable disease (evident disease or positive marker levels), complete remission was obtained in 16 (84%), but 5 of these relapsed. Therefore, treatment with PVB failed in 8 out of 19 patients (42%) with measurable disease. Toxicity was evident, but no patient died of it. Menses were regular in 11 patients whose initial surgery was conservative. PVB regimen is an effective but not a satisfactory treatment. The considerable failure rate of PVB treatment suggests the investigation of other regimens.

A method of hypofractionated accelerated radiotherapy (3 weekly fractions of 6 Gy over 2 weeks to a total tumor dose of 36 Gy) was used as single modality in 14 patients with osteogenic sarcoma for palliative treatment of the primary tumor site (six cases) or skeletal metastases (15 sites). A durable response, radiologically assessed, was obtained in 17 of the 21 (81%) irradiated sites. When this irradiation modality was combined with chemotherapy, to treat patients presenting with synchronous metastases (eight cases) or refusing amputation (five cases), a radiologically assessed response was observed in 12 of 13 (92%). In no case did a local recurrence occur before surgery or death because of progressive disease elsewhere. Of the seven patients who later had to undergo ablative surgery, a 100% and 95% tumor necrosis was observed in 6 and 1, respectively. Because of intralesional resection of primary osteogenic sarcoma after preoperative chemotherapy, seven additional patients were irradiated. None recurred at the level of the primary site. Although effective in inducing remission of osteogenic sarcoma, this irradiation method produced severe damages to normal tissues in a high proportion of patients.

In sera of 38 patients with sarcoidosis, assayed for antiviral antibody to Rubella, Measles, Cytomegalovirus (CMV), adenovirus, Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), different incidence of seropositivity have been found, according to the virus assayed. Interestingly all patients were seropositive to rubella virus with high titres compared to data obtained from normal age matched population. These data indicate that in Sarcoidosis an altered antibody response of post-primary type can be found.

The results are reported of an immunological study conducted on 37 cases of active sarcoidosis, in which some in vivo and in vitro tests related to the cell-mediated immunitary response were effected. The results are discussed, with relation to the clinical use of the immunological tests adopted, and their immunopathogenetic significance. In particular, the occurrence of false-positive and false-negative results in the in vitro Kveim antigen test (LMT) using the antigen preparations currently available, limit its use in clinical practice.

Bronchoalveolar lavage (BAL) was performed in a group of 25 patients with pulmonary sarcoidosis in order to monitor variations in alveolar lymphocytes (AL) in comparison to the clinical evolution of the disease. Two BAL were performed in each patient, the second 6-12 months after the first (8.9 +/- 3, M +/- SD). Twelve patients were classified as improved and 13 as unimproved on the basis of a score of changes in the clinical picture, x-ray, respiratory function, immunological and biochemical tests. There was a significant decrease (p less than 0.001) of the percentage of AL in 66% of cases in the improved group, but not in the unimproved group, where, on the contrary, it was possible to observe an increase in the percentage of AL in 46% of these cases (n.s.). In 9 of 11 patients followed for 1-5 years with at least 3 BAL, AL behaviour correlated with clinical evolution. On the basis of the parameters studied, it was possible to show a correlation between lymphocytes, alveolitis and clinical evolution, especially in patients with an improved course. While a single BAL does not seem to be sufficient to show the course of the disease, repeated long-term washings allow a more accurate staging of sarcoidosis and can give early warning of relapses even when the conventional parameters (clinical, radiological and functional) are unchanged. Our aim was to look for a simpler parameter, which could be used routinely by even unspecialized laboratories, who are not able to type lymphocytes.

Fifteen patients with metastatic osteogenic sarcoma (OS) were treated with a combination of Vincristine (1.4 mg/m2), high-dose Methotrexate (8 g/m2), and Cisplatin (120 mg/m2 as a 72-h continuous infusion). The overall response rate was 66% [5 complete response (CR) and 5 partial response (PR)]. Four of the six patients not previously treated had a CR. Toxicity from this regimen was moderate and never life-threatening. In no case was impairment of the renal function observed, and the clearance of high-dose Methotrexate was never delayed.

Leucocyte inhibition migration test (LMT) with BCG and PPD was applied in pulmonary tuberculosis, lung cancer and sarcoidosis. No significant differences were noticed in the results obtained with each of the two antigenic materials; nevertheless, one case lobectomized of lung cancer successively treated with chemiotherapie and immunostimulation with BCG presented LMT positivity with BCG and negativity with PPD. The unpublished results of the former investigations carried out with brute tuberculin (LMT) on patients with pulmonary tuberculosis are here reported no significant difference was noticed between the results obtained with brute tuberculin, and the results with PPD. The still unsettled problem presented by the lack of inhibition in the presence of PPD in leucocyte migration test in patients with areactive (AA) and intermediate areactive (AI) tuberculosis is also briefly discussed. Finally, the existence of a dissociation between the cutaneous delayed test and the in vitro test for the detection of cellular sensibilisation is confirmed even when LMT is applied either in the presence of BCG or of PPD.

In the last few years, we have adopted the following immunological techniques for the study of hilarmediastinal lymphadenopathies: the E and EAC rosette tests (composition of the lymphocyte population) for an evaluation of the general immunological picture, the delayed-type cutaneous tests to reveal the specific picture of cell-mediated immune responses, and the leucocyte migration inhibition test against related and unrelated antigens. This cellular technique was integrated with the determination of precipitating and agglutinating antibodies against the same antigens. Data are reported regarding tubercular and sarcoid lymphadenopathies, Hodgkin's disease, and secondary neoplastic lymphadenopathy with prevalent intratoracic localization. The techniques used demonstrated that tubercular lymphadenopathy is associated with a well defined immunological profile which is both humoral and cellular. Sarcoid lymphadenopathy (thoracic sarcoidosis) showed a specific, well characterized immunological picture as regards cell-mediated immune responses. In Hodgkin's disease (hilarmediastinal lymphadenopathy) the immunological technique showed up a general, depressed immunological picture, particularly as regards the cell-mediated immunitary response, presumably partly due to the treatment given (physical and pharmacological therapy). Secondary neoplastic lymphadenopathy showed a similar pattern, as far as the immunological parameters used until now are concerned. On the basis of experience gained to date, we believe that the immunological techniques can make a contribution to diagnostic and clinical studies of tubercular and sarcoid lymphadenopathies.

The movement of ions and water across the membranes of bronchial cells is part of the control of the bronchial obstructive response to physical stimuli. In a double-blind, randomized, crossover study, we compared the effect of an aerosol of the loop diuretic furosemide with that of a placebo on the early (within 60 minutes) and late (4 to 12 hours) asthmatic responses to a specific inhaled allergen. We studied 11 subjects with mild allergic asthma, who had both early and late asthmatic responses to a specific inhaled allergen in a preliminary challenge. After placebo administration, the maximal changes (mean +/- SE) from base line in the forced expiratory volume in one second (FEV1) and specific airway resistance were, respectively, a decrease of 35 +/- 4 percent and an increase of 288 +/- 56 percent between 0 and 60 minutes after inhalation of the allergen (early response) and a decrease of 35 +/- 5 percent and an increase of 301 +/- 40 percent between 4 and 12 hours (late response). After furosemide administration (4 ml; 10 mg per milliliter), the early response to inhaled allergen was markedly attenuated in all the subjects, and the late response in all but one. The maximal changes in the FEV1 and specific airway resistance were, respectively, a decrease of 11 +/- 2 percent and an increase of 61 +/- 2 percent between 0 and 60 minutes and a decrease of 20 +/- 4 percent and an increase of 178 +/- 25 percent between 4 and 12 hours (P less than 0.05 for all comparisons). No significant differences were seen in the bronchoconstrictor response to inhaled methacholine after furosemide or placebo administration. We conclude that a furosemide-sensitive mechanism in the airways is involved in the pathogenesis of the reactions of patients with allergic asthma. Whether inhaled furosemide might be useful in the treatment of allergic asthma is uncertain and will require further study.

Eight hundred and two consecutive symptomatic outpatients (with asthma and rhinitis) were studied to evaluate the incidence of prick test positivity to cat and dog danders and the association of exposure to these animals in the home, as revealed by a standard questionnaire. 14.3% were found to be skin positive to cat and/or dog danders. The incidence of cutaneous hypersensitivity to cat and/or dog danders was 25% in the 216 subjects who kept animals, significantly higher (p less than 0.0005) than the 10.4% of 586 subjects who did not keep animals. In the 57 subjects who owned both dogs and cats, a significantly higher incidence of skin hypersensitivity was found compared to the other subjects. Our data does not demonstrate a greater incidence in sensitivity to cat danders compared to dog danders, or increased sensitization to dermatophagoides pteronyssinus, nor a different incidence of clinical manifestations (asthma and rhinitis) between those with animals in the house and those without.

Differentiation between diffuse lung tumours and interstitial pulmonary diseases often requires open lung biopsy. We report two cases of bronchiolo-alveolar carcinoma presenting as diffuse pulmonary disease, in which the diagnosis was made by cytological examination of bronchoalveolar lavage. Bronchoalveolar lavage can, thus, differentiate between diffuse lung tumours and interstitial pulmonary diseases.

Results of two consecutive treatment programs for advanced neuroblastoma, including sequential hemibody irradiation, are analyzed and compared. The first treatment program (I-TP) included one single-fraction (7 Gy) irradiation to the upper and lower halves of the body as consolidation of remission achieved by previous chemotherapy with CDDP and VP16. A fractionated technique (2 Gy daily for 4 consecutive days to each hemibody) was used in the second treatment program (II-TP) for children in remission following a combination of CDDP + VP16 and ADM + VCR + CTX. In both treatment programs, chemotherapy was continued according to the same pre-radiation regimen following the two sessions of hemibody irradiation. Overall response rate to pre-radiation chemotherapy was 84% and 60% for I-TP and II-TP, respectively. Thirty-month overall progression-free survival was 0 for I-TP and 20% for II-TP. No treatment-related fatalities occurred. In the subsets of patients who reached complete or good partial remission during the pre-radiation chemotherapeutic phase, 30-month progression-free survival in I-TP and II-TP was 0 and 33%, respectively. The role of fractionated hemibody irradiation in prolonging the progression-free survival can be inferred.